# JMT106 Injection in the Treatment of Advanced Solid Tumors

> **NCT07275073** · PHASE1 · RECRUITING · sponsor: **Shanghai JMT-Bio Inc.** · enrollment: 200 (estimated)

## Conditions studied

- Advanced Solid Tumor
- Lung Squamous Cell Carcinoma
- Hepatocellular Carcinoma

## Interventions

- **DRUG:** JMT106 Injection

## Key facts

- **NCT ID:** NCT07275073
- **Lead sponsor:** Shanghai JMT-Bio Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-25
- **Primary completion:** 2026-11-05
- **Final completion:** 2028-11-15
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2025-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07275073

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07275073, "JMT106 Injection in the Treatment of Advanced Solid Tumors". Retrieved via AI Analytics 2026-08-22 from https://api.ai-analytics.org/clinical/NCT07275073. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*